Gastric Cancer Drugs Global Market Report 2022 – By Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), By End User (Hospitals, Clinics), By Route of Administration (Oral, Parenteral) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 175 | Published : March 2022 | SKU CODE : 7231 | Delivery Time: 2-3 business days | Format :


The gastric cancer drugs market consists of sales of drugs for gastric cancer. Gastric cancer, also known as stomach cancer, is the formation of abnormal cells on the lining of stomach resulting in stomach pain and indigestion.

The main types of gastric cancer drugs are doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib and trastuzumab. Sunitinib is a chemotherapeutic agent and receptor tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumour (GIST). The drugs are administered through oral and parenteral that are used by hospitals, clinics, and others

The global gastric cancer drugs market size is expected to grow from $2.63 billion in 2021 to $3.05 billion in 2022 at a compound annual growth rate (CAGR) of 15.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global gastric cancer drug market size is expected to reach $5.18 billion in 2025 at a CAGR of 14.2%.

Increasing number of obesity cases and smoking population increased number of people suffering from gastric cancer. Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. According to the estimates of American Institute for Cancer Research for 2020, about 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs.

Stringent regulations and policies for approval of the drugs restrain the market for gastric cancer drugs. Different regions have their own set of rules, guidelines and regulations set by their respective drugs regulation board. For example, the USFDA regulations for American pharmaceuticals states various conditions with regards to safety and effectiveness of the drug as well as certain labeling requirements. Similarly, the European medicines agency (EMA) gives licenses to the approved drugs before they can be marketed or commercialized in the European continent. Teysuno, a drug for advanced gastric cancer can be only obtained through a valid prescription and the protocol is that every company must assess the effects of using Teysuno and must list out the precautions to be taken by patients and healthcare providers to minimize any possible side effects. These regulations hinder the growth of the gastric cancer drugs market.

Many companies are using combination therapies to cure gastric cancer. Combination therapies help in treating patients with two or more drugs for a single disease and help in better treating the patients. For instance, in 2019, the USFDA has approved Taiho Oncology Inc’s combined product LONSURF trifluridine/tipiracil for pre-treated metastatic gastric cancer. This approval is significant for patients living with advanced gastric or GEJ (gastroesophageal junction) adenocarcinoma who have limited effective treatment options after failure of standard treatment options. Advances in the drugs for treatment of gastric cancer will have a positive influence on the gastric cancer drugs’ market

The gastric cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, FDA's Current Good Manufacturing Practice (CGMP) regulation lays down minimum requirements for the methods and facilities used in manufacturing, processing, and packing of a drug product and ensures the quality of drugs produced by manufacturers. Moreover, FDA's guidance provides recommendations to applicants for cancer clinical trials and shows support in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications.

On April 2019, AstraZeneca, a multinational pharmaceutical and biopharmaceutical company acquired Daiichi Sankyo for $1.35 billion. This acquisition will help AstraZeneca to jointly develop drug Trastuzumab Deruxtecan with Daiichi Sankyo. This drug would help to treat people suffering from breast and gastric cancer. Daiichi Sankyo headquarted at Japan is a global pharmaceutical company which offers innovative products and a robust pipeline for cancer treatment.

Major players in the gastric cancer drugs market are Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche, GlaxoSmithKline PLC, Bristol-Myers Squibb, Sanofi, Pfizer Inc., AstraZeneca, Bayer Healthcare, Abbott, AROG Pharmaceuticals, Ipsen Biopharmaceuticals, Array Biopharma, Taiho Oncology, AstraZeneca, ARIAD Pharmaceuticals, Ono Pharmaceutical, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, Imugene Limited, Boehringer Ingelheim, Daiichi-Sankyo, Danaher corporation.

North America was the largest region in the gastric cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the gastric cancer drug market during the forecast period. The regions covered in the global gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The global gastric cancer drugs market is segmented -

1) By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab

2) By End-User: Hospitals, Clinics, Others

3) By Route of Administration: Oral, Parenteral

    Table Of Contents

    1. Executive Summary

    2. Gastric Cancer Drugs Market Characteristics

    3. Gastric Cancer Drugs Market Trends And Strategies

    4. Impact Of COVID-19 On Gastric Cancer Drugs

    5. Gastric Cancer Drugs Market Size And Growth

    5.1. Global Gastric Cancer Drugs Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Gastric Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Gastric Cancer Drugs Market Segmentation

    6.1. Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Doxorubicin Hydrochloride

    Sunitinib

    Docetaxel

    Mitomycin

    Fluorouracil

    Imatinib

    Trastuzumab

    6.2. Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospitals

    Clinics

    Others

    6.3. Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oral

    Parenteral

    7. Gastric Cancer Drugs Market Regional And Country Analysis

    7.1. Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Gastric Cancer Drugs Market

    8.1. Asia-Pacific Gastric Cancer Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Gastric Cancer Drugs Market

    9.1. China Gastric Cancer Drugs Market Overview

    9.2. China Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Gastric Cancer Drugs Market

    10.1. India Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Gastric Cancer Drugs Market

    11.1. Japan Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Gastric Cancer Drugs Market

    12.1. Australia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Gastric Cancer Drugs Market

    13.1. Indonesia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Gastric Cancer Drugs Market

    14.1. South Korea Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Gastric Cancer Drugs Market

    15.1. Western Europe Gastric Cancer Drugs Market Overview

    15.2. Western Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Gastric Cancer Drugs Market

    16.1. UK Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Gastric Cancer Drugs Market

    17.1. Germany Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Gastric Cancer Drugs Market

    18.4. France Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Gastric Cancer Drugs Market

    19.1. Eastern Europe Gastric Cancer Drugs Market Overview

    19.2. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Gastric Cancer Drugs Market

    20.1. Russia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Gastric Cancer Drugs Market

    21.1. North America Gastric Cancer Drugs Market Overview

    21.2. North America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Gastric Cancer Drugs Market

    22.1. USA Gastric Cancer Drugs Market Overview

    22.2. USA Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Gastric Cancer Drugs Market

    23.1. South America Gastric Cancer Drugs Market Overview

    23.2. South America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Gastric Cancer Drugs Market

    24.1. Brazil Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Gastric Cancer Drugs Market

    25.1. Middle East Gastric Cancer Drugs Market Overview

    25.2. Middle East Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Gastric Cancer Drugs Market

    26.1. Africa Gastric Cancer Drugs Market Overview

    26.2. Africa Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Gastric Cancer Drugs Market Competitive Landscape And Company Profiles

    27.1. Gastric Cancer Drugs Market Competitive Landscape

    27.2. Gastric Cancer Drugs Market Company Profiles

    27.2.1. Eli Lilly and company

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Novartis

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Merck KGaA

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Otsuka Pharmaceutical

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. F. Hoffmann-La Roche

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Gastric Cancer Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Gastric Cancer Drugs Market

    30. Gastric Cancer Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: Eli Lilly and company Financial Performance
  • Table 47: Novartis Financial Performance
  • Table 48: Merck KGaA Financial Performance
  • Table 49: Otsuka Pharmaceutical Financial Performance
  • Table 50: F. Hoffmann-La Roche Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: Eli Lilly and company Financial Performance
  • Figure 47: Novartis Financial Performance
  • Figure 48: Merck KGaA Financial Performance
  • Figure 49: Otsuka Pharmaceutical Financial Performance
  • Figure 50: F. Hoffmann-La Roche Financial Performance
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Neurostimulation Devices Global Market Report 2022 – By Product (Implantable Devices, External Devices), By Application (Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease), By End User (Hospitals, Rehabilitation Centers, Medical Clinic), By Implantable Devices (Cochlear Implants, Deep Brain Stimulation, Spinal Cord Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), By External Devices (Transcranial Magnetic Stimulation (TMS), Transcutaneous Electrical Nerve Stimulation (TENS)) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Liposomal Drug Delivery Devices Global Market Report 2022 – By Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B), By Application (Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy), By End User (Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Thyroid Cancer Drugs Global Market Report 2022 – By Drug Type (Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Others), By End Users (Hospitals, Oncology Clinics, Research Organizations, Others), By Type (Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Others) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Diagnostics Global Market Report 2022 – By Products (Companion Diagnostics, Molecular Diagnostics), By End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users), By Method (Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging), By Application (Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Monoclonal Antibodies Global Market Report 2022 – By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix)), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer), By End User (Hospitals And Clinics, Research Laboratories, Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Vaccines Global Market Report 2022 – By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), By Cancer Type (Prostate, Cervical, Colorectal, Throat), By End-User (Cancer Treatment Centers, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy), By Application (Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers), By Distribution Channel (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Clinical Decision Tools Global Market Report 2022 – By Type (Risk Assessment Tool(RAT), Qcancer), By End-User (Hospital, Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)